Kezar Life Sciences Inc (NASDAQ:KZR) — Stock Price
Kezar Life Sciences Inc (NASDAQ:KZR) is currently trading at $0.17 USD, down 5.71% today. Over the past 52 weeks, shares have ranged between $0.12 and $7.45. This page tracks Kezar Life Sciences Inc's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Kezar Life Sciences Inc stock valuation.
Kezar Life Sciences Inc (KZR) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Kezar Life Sciences Inc's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Kezar Life Sciences Inc Income Statement — Revenue, Profit & Earnings by Year
Kezar Life Sciences Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $7.00 Million | $0.00 | $0.00 |
| Cost of Revenue | $897.00K | $1.04 Million | $1.07 Million | $1.02 Million | $1.51 Million |
| Gross Profit | $-897.00K | $-1.04 Million | $7.00 Million | $-1.02 Million | $-1.51 Million |
| Research & Development | $33.76 Million | $65.74 Million | $85.70 Million | $51.01 Million | $38.94 Million |
| SG&A | $18.51 Million | $23.39 Million | $26.54 Million | $20.15 Million | $15.72 Million |
| Total Operating Expenses | $51.37 Million | $90.61 Million | $118.42 Million | $71.16 Million | $53.15 Million |
| Operating Income | $-52.27 Million | $-90.61 Million | $-111.42 Million | $-71.16 Million | $-54.66 Million |
| EBITDA | $-51.37 Million | $-81.10 Million | $-99.25 Million | $-70.14 Million | $-52.96 Million |
| EBIT | $-52.27 Million | $-82.14 Million | $-100.32 Million | $-71.16 Million | $-54.47 Million |
| Interest Expense | $1.37 Million | $1.59 Million | $1.55 Million | $1.19 Million | $159.00K |
| Income Before Tax | $-56.03 Million | $-83.74 Million | $-101.87 Million | $-68.24 Million | $-54.63 Million |
| Income Tax Expense | — | — | $898.11K | $-2.92 Million | $-1.35 Million |
| Net Income | $-56.03 Million | $-83.74 Million | $-101.87 Million | $-65.32 Million | $-54.63 Million |
Kezar Life Sciences Inc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Kezar Life Sciences Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $76.65 Million | $144.68 Million | $221.24 Million | $299.57 Million | $217.93 Million |
| Total Current Assets | $75.73 Million | $137.49 Million | $206.95 Million | $285.72 Million | $211.65 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $0.00 | $90.50 Million | $165.88 Million | $236.10 Million | $145.47 Million |
| Net Receivables | $1.93 Million | $424.00K | $2.29 Million | — | $70.00K |
| Inventory | — | — | — | — | $2.50 Million |
| Property, Plant & Equipment | — | — | — | $3.43 Million | $3.28 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $6.57 Million | $27.77 Million | $33.66 Million | $29.70 Million | $21.06 Million |
| Total Current Liabilities | $6.57 Million | $20.33 Million | $17.74 Million | $11.00 Million | $8.21 Million |
| Long-term Debt | — | $5.11 Million | $10.07 Million | $9.83 Million | $9.62 Million |
| Net Debt | $-69.55 Million | $-25.57 Million | $-16.56 Million | $-19.19 Million | $-48.84 Million |
| Total Stockholder Equity | $70.07 Million | $116.92 Million | $187.57 Million | $269.87 Million | $196.88 Million |
| Retained Earnings | $-490.53 Million | $-434.50 Million | $-350.76 Million | $-248.89 Million | $-180.65 Million |
Kezar Life Sciences Inc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Kezar Life Sciences Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-51.78 Million | $-74.21 Million | $-81.64 Million | $-58.85 Million | $-42.44 Million |
| Capital Expenditures | $8.00K | $29.00K | $1.81 Million | $1.58 Million | $316.00K |
| Free Cash Flow | $-51.78 Million | $-74.24 Million | $-83.45 Million | $-60.42 Million | $-42.75 Million |
| Investing Cash Flow | $92.46 Million | $80.43 Million | $76.05 Million | $-91.39 Million | $-28.44 Million |
| Financing Cash Flow | $-10.59 Million | $103.00K | $638.00K | $127.86 Million | $112.58 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $8.96 Million | $13.01 Million | $18.14 Million | $14.01 Million | $7.60 Million |
| Depreciation | $-1.10 Million | $1.04 Million | $1.07 Million | $1.02 Million | $1.51 Million |
| Change in Cash | $30.13 Million | $6.26 Million | $-4.96 Million | $-22.43 Million | $41.65 Million |
Kezar Life Sciences Inc Earnings History — EPS Actual vs. Analyst Estimates
Track Kezar Life Sciences Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | -0.70 | -0.98 | +28.53% |
| Mar 30, 2026 | -1.05 | -1.31 | +19.57% |
| Nov 12, 2025 | -1.53 | -0.26 | -488.46% |
| Aug 13, 2025 | -1.87 | -0.28 | -567.86% |
| Jun 18, 2025 | -2.00 | -2.65 | +24.53% |
| Mar 12, 2025 | -3.00 | -2.76 | -8.70% |
| Nov 13, 2024 | -2.78 | -3.15 | +11.75% |
| Aug 13, 2024 | -0.27 | -0.32 | +15.63% |